Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118981 | 0.92 | ALDH1A1 (0.40) | ALDH1A1PLA2G2A | |
| SCHEMBL5123108 | 0.92 | S1PR3 (0.44) | HRH1HTR6ALDH1A1 | |
| SCHEMBL14177944 | 0.91 | PLA2G2A (0.40) | ALDH1A1PLA2G2A | |
| SCHEMBL27744615 | 0.89 | FEN1 (0.46) | HRH1HTR6ALDH1A1PLA2G2A | |
| SCHEMBL14177947 | 0.87 | KDM4E (0.51) | — | |
| SCHEMBL5117212 | 0.83 | L3MBTL1 (0.52) | ALDH1A1PLA2G2A | |
| SCHEMBL14177963 | 0.81 | LMNA (0.45) | — | |
| SCHEMBL14177959 | 0.80 | GAA (0.48) | ALDH1A1 | |
| SCHEMBL4893109 | 0.79 | RECQL (0.55) | — | |
| SCHEMBL14177957 | 0.79 | L3MBTL1 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996553-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008144463-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | HRH1 1799/4885HTR6 3913/4885ALDH1A1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.